Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DXWP72
|
|||
| Drug Name |
SEphB4-HSA
|
|||
| Drug Type |
Recombinant protein
|
|||
| Indication | Kaposi sarcoma [ICD-11: 2B57; ICD-9: 176] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [2] | ||
| Company |
VasGene Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ephrin type-B receptor 2 (EPHB2) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Axon guidance | |||
| Panther Pathway | Angiogenesis | |||
| Pathway Interaction Database | EPHB forward signaling | |||
| EphrinB-EPHB pathway | ||||
| Syndecan-2-mediated signaling events | ||||
| Ephrin B reverse signaling | ||||
| Reactome | EPH-Ephrin signaling | |||
| L1CAM interactions | ||||
| EPHB-mediated forward signaling | ||||
| EPH-ephrin mediated repulsion of cells | ||||
| WikiPathways | Transcriptional activation by NRF2 | |||
| NLR Proteins | ||||
| Regulation of Microtubule Cytoskeleton | ||||
| L1CAM interactions | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03993106) A Study of sEphB4-HSA in Kaposi Sarcoma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | National Cancer Institute Drug Dictionary (drug name SEphB4-HSA). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.